Phase 2 N=72 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Ebola Virus Infection
Primary: Mortality — 13; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=115 VSV-ZEBOV Geneva Vaccine Trial
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Phase 1 N=513 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
Phase 1 N=39 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Phase 3 N=680 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Ebola Virus
Primary: Mortality — 93; 61; 52; 84 deaths
Phase 1 N=39 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
Ebola Virus
Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants
Phase 3 N=8,651 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Hemorrhagic Fever, Ebola
Primary: Laboratory-confirmed Ebola (Study Diagnostics) — 0; 0 Participants
Phase 1 N=19 Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Healthy Adult Immune Responses to Vaccine
Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants
Phase 1 N=40 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
N/A N=37 PREVAIL VII: Cataract Surgery in Ebola Survivors
Cataract
Primary: Proportion of EVD Survivors With Evidence of Persistence of Ebola Viral RNA in Ocular Tissue — 0 Participants
Phase 2 N=1,500 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Ebola Virus
Primary: Serious Adverse Events. — 6; 6; 8 Participants — p=0.68
Phase 2 N=251 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Ebola
Primary: Number of Participants With Solicited Adverse Events Following V920 Vaccination — 5; 1; 2; 1 Participants
Phase 3 N=606 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
Hemorrhagic Fever, Ebola
Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants
Phase 2 N=38 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Ebola
Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples
Phase 2 N=3,013 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
Virus Diseases
Primary: Number of Subjects With Solicited Local Adverse Events — 356; 57; 3; 0 Participants
Phase 1 N=26 A Study of a New Vaccine Against Two Types of Ebola
Ebola
Primary: Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms…
Phase 1 N=40 Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
Ebola Virus Disease
Primary: Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse…
Phase 2 N=4,786 Partnership for Research on Ebola VACcinations
Ebola Virus Disease
Primary: Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response — 40.9; 75.7; 81.1; 2.7 percentage of participants — p=<.001
Phase 3 N=1,197 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
Prevention of Ebola Infection
Primary: Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody — 1183.9; 1266.0; 1346.0; 1291.9 EU/mL — p=<0.001
Phase 3 N=970 A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
Ebola
Primary: Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA)…
Phase 2 N=1,073 Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Hemorrhagic Fever, Ebola
Primary: Number of Participants With Adverse Events (Day 29) — 96; 17; 68; 17 Participants
Phase 2 N=600 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
Virus Diseases
Primary: Number of Subjects With Solicited Local Symptoms, Overall — 127; 60; 4; 0 Participants
Phase 1 N=61 A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)
Ebola Disease · Immunisation
Primary: Number of Participants With Clinical Safety Laboratory Adverse Events — 2; 5; 4; 2 Participants
Phase 2 N=574 Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Hemorrhagic Fever, Ebola
Primary: Part 1, Part 2 (Group 2): Number of Participants With Unsolicited Adverse Events — 33; 10; 32; 3 Participants
Phase 3 N=1,018 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
Ebola Virus Disease
Primary: Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8) — 12; 51; 17; 14 Participants
Phase 2 N=421 A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
Ebola Viral Disease
Primary: Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3) — 4; 6; 6; 62 Participants
N/A N=1,046 Febrile Illness in Kinshasa and Kimpese
Febrile Illness
Primary: Proportion of Survival With Symptom Resolution — 96.9 percentage of participants
Phase 2 N=50 Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
Ebola Virus Disease
Primary: Number of Participants With Solicited Local (at the Administration Site) Adverse Events — 18 Participants
Phase 2 N=23 Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Infectious Mononucleosis
Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants
N/A N=300 Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants